Your browser doesn't support javascript.
Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
Ganesh, Ravindra; Philpot, Lindsey M; Bierle, Dennis M; Anderson, Ryan J; Arndt, Lori L; Arndt, Richard F; Culbertson, Tracy L; Destro Borgen, Molly J; Hanson, Sara N; Kennedy, Brian D; Kottke, Brian B; Larsen, Jennifer J; Ramar, Priya; Rosedahl, Jordan K; Seville, Maria Teresa; Speicher, Leigh L; Tulledge-Scheitel, Sidna M; Wilker, Caroline G; Razonable, Raymund R.
  • Ganesh R; Mayo Clinic, Rochester, Minnesota, USA.
  • Philpot LM; Mayo Clinic, Rochester, Minnesota, USA.
  • Bierle DM; Mayo Clinic, Rochester, Minnesota, USA.
  • Anderson RJ; Mayo Clinic, Rochester, Minnesota, USA.
  • Arndt LL; Mayo Clinic Health System, Eau Claire, Wisconsin, USA.
  • Arndt RF; Mayo Clinic Health System, Eau Claire, Wisconsin, USA.
  • Culbertson TL; Mayo Clinic Health System, Mankato, Minnesota, USA.
  • Destro Borgen MJ; Mayo Clinic, Rochester, Minnesota, USA.
  • Hanson SN; Mayo Clinic Health System, Mankato, Minnesota, USA.
  • Kennedy BD; Mayo Clinic Health System, Lake City, Minnesota, USA.
  • Kottke BB; Mayo Clinic Health System, Mankato, Minnesota, USA.
  • Larsen JJ; Mayo Clinic, Rochester, Minnesota, USA.
  • Ramar P; Mayo Clinic, Rochester, Minnesota, USA.
  • Rosedahl JK; Mayo Clinic, Rochester, Minnesota, USA.
  • Seville MT; Mayo Clinic Arizona, Phoenix, Arizona, USA.
  • Speicher LL; Mayo Clinic, Jacksonville, Florida, USA.
  • Tulledge-Scheitel SM; Mayo Clinic, Rochester, Minnesota, USA.
  • Wilker CG; Mayo Clinic Health System-Franciscan Healthcare, La Crosse, Wisconsin, USA.
  • Razonable RR; Mayo Clinic, Rochester, Minnesota, USA.
J Infect Dis ; 224(8): 1278-1286, 2021 10 28.
Article in English | MEDLINE | ID: covidwho-1316825
ABSTRACT

BACKGROUND:

Bamlanivimab and casirivimab-imdevimab are authorized for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in high-risk patients. We compared the outcomes of patients who received these therapies to identify factors associated with hospitalization and other clinical outcomes.

METHODS:

Adult patients who received monoclonal antibody from 19 November 2020 to 11 February 2021 were selected and divided into those who received bamlanivimab (n = 2747) and casirivimab-imdevimab (n = 849). The 28-day all-cause and COVID-19-related hospitalizations were compared between the groups.

RESULTS:

The population included 3596 patients; the median age was 62 years, and 50% were female. All had ≥1 medical comorbidity; 55% had multiple comorbidities. All-cause and COVID-19-related hospitalization rates at 28 days were 3.98% and 2.56%, respectively. After adjusting for medical comorbidities, there was no significant difference in all-cause and COVID-19-related hospitalization rates between bamlanivimab and casirivimab-imdevimab (adjusted hazard ratios [95% confidence interval], 1.4 [.9-2.2] and 1.6 [.8-2.7], respectively). Chronic kidney, respiratory and cardiovascular diseases, and immunocompromised status were associated with higher likelihood of hospitalization.

CONCLUSIONS:

This observational study on the use of bamlanivimab and casirivimab-imdevimab in high-risk patients showed similarly low rates of hospitalization. The number and type of medical comorbidities are associated with hospitalizations after monoclonal antibody treatment.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / COVID-19 Type of study: Diagnostic study / Etiology study / Observational study / Prognostic study / Randomized controlled trials / Risk factors Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: J Infect Dis Year: 2021 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / COVID-19 Type of study: Diagnostic study / Etiology study / Observational study / Prognostic study / Randomized controlled trials / Risk factors Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: J Infect Dis Year: 2021 Document Type: Article Affiliation country: Infdis